Form 4: BioMarin Executive Erin Burkhart Reports Stock Transactions

Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., reports acquisition and disposal of company stock and stock options.

Summary

• On March 14, 2025, Erin Burkhart disposed of 823 shares of BioMarin common stock at a price of $69.44.
• On March 17, 2025, Burkhart acquired 5,970 shares of BioMarin common stock as restricted stock units.
• Also on March 17, 2025, Burkhart acquired options to purchase 9,230 shares of BioMarin common stock at an exercise price of $71.55, vesting in installments starting March 17, 2026.
• Following these transactions, Burkhart directly owns 18,252 shares of common stock and options to purchase 9,230 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock transactions by an executive, which is a routine occurrence. There is no indication of positive or negative implications for the company's performance.

Positives

• The grant of restricted stock units and stock options to a key executive could be seen as a positive sign of alignment between management and shareholder interests.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with those of shareholders.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar compensation strategies for their executives.

Stakeholder Impact

• Shareholders may be interested in the transactions as they provide insight into management's holdings and potential incentives.

Key Dates